Brainify.AI to Showcase Innovation in Precision Psychiatry at J.P. Morgan Healthcare Conference 2026
SAN FRANCISCO, CA — Brainify.AI, a leader in artificial intelligence-driven neuro-biomarkers, is pleased to announce that Ivan Mishanin, Co-founder and COO, will be attending the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026.
The J.P. Morgan Healthcare Conference is the industry's largest and most informative healthcare investment symposium, bringing together global industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.
As Brainify.AI continues to redefine the landscape of Precision Psychiatry, the conference serves as a pivotal platform to engage with strategic partners and investors dedicated to solving the most pressing challenges in the CNS (Central Nervous System) space.
"The era of data-driven psychiatry has arrived. We are no longer just discussing the potential of AI; we are deploying it to de-risk drug development and personalize treatment pathways for patients who have waited too long for effective solutions. I look forward to sharing Brainify.AI's latest milestones and exploring new collaborations that will define the next year of growth." — Ivan Mishanin
Key Focus Areas for Brainify.AI at JPM2026:
- De-risking Clinical Trials: Utilizing AI-powered digital biomarkers to increase the probability of success in CNS drug development.
- Predictive Diagnostics: Showcasing how our platform predicts patient response to psychiatric treatments with unprecedented accuracy.
- Strategic Partnerships: Engaging with biotech and pharmaceutical leaders to integrate Brainify.AI's technology into next-generation therapeutic pipelines.
Ivan Mishanin will be available for one-on-one meetings throughout the week in San Francisco. To schedule a meeting, please contact our team at info@brainify.ai or connect with Ivan directly via LinkedIn.
About Brainify.AI
Brainify.AI is a biotech company focused on transforming the treatment of mental health disorders through artificial intelligence. By leveraging neuro-biomarkers and advanced machine learning, Brainify.AI provides pharmaceutical companies and clinicians with the tools to personalize treatment and accelerate the development of life-changing psychiatric medications.